Intercept Pharmaceuticals Inc
Most Recent
Benchmark Indexes Continue to Outperform IBB and XBI
The iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) provide investors with an opportunity to hold a basket of stocks from different subindustries from the biotech sector.
Array BioPharma: Why Wall Street Analysts Are Positive
Of the eight analysts tracking Array BioPharma in June, three recommended a “strong buy,” while five recommended a “buy.”
What Spark Therapeutics’ Valuation Trend Indicates
Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
JPMorgan Upgrades Ophthotech: Stock Skyrockets
Ophthotech (OPHT) rose 11.6% for the week ended June 3, 2016, and outperformed the SPDR S&P 500 ETF (SPY). It was one of the top mid-cap performers.
What Analysts Recommend for Array BioPharma Stock
As of August 15, analysts’ target price for ARRY is $23.57, which implies a ~71.7% return over the next 12 months based on the stock’s August 14 price of $13.73.
If You Own Intercept Stock, Should You Sell It Now?
On Monday, Intercept Pharmaceuticals (NASDAQ:ICPT) stock lost 39.7% and closed at $46.70 with a market cap of $1.54 billion.
Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor
Intercept Pharmaceuticals (ICPT) closed at $80.99 on June 12, 0.90% higher than its previous close, 10.93% above its 52-week low of $73.01, and 39.44% below its 52-week high of $133.74.
CymaBay Therapeutics: What Investors Should Watch For
CymaBay Therapeutics (CBAY) is currently enrolling patients in its Phase 3 registrational trial, ENHANCE, to evaluate the use of its investigational PPARδ (peroxisome proliferator-activated receptor delta) agonist, seladelpar, in PBC (primary biliary cholangitis).
Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.
A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline
In this series, we’ll analyze three pharmaceutical companies with focused nonalcoholic steatohepatitis pipelines.
Analyzing Axovant Sciences’ Valuation Metrics
In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given it a “buy” rating, and five have given it a “hold.”
Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6
On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26.
Analysts Are Bullish on Viking Therapeutics Stock
On June 1, Viking Therapeutic had a consensus 12-month target price of $10.63, which implies a 12-month investment return potential of ~4.7%.
Viking Therapeutics Stock Rose 101% on May 31
On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.
Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”
An In- Depth Look at Intercept Pharmaceuticals’ Ocaliva
Intercept Pharmaceuticals is evaluating a development strategy for Ocaliva in other indications.
Analysts’ Ratings for FibroGen and Its Peers in April 2018
Of the seven analysts covering FibroGen in April, five have given the stock “strong buy” ratings, while two have given it “hold” ratings.
Which Gilead Sciences Portfolio Could Give a Long-Term Boost
NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.
GILD’s Positive Results from Phase 2 Trial Evaluating Selonsertib as NASH Therapy
Gilead Sciences (GILD) is preparing to pose strong competition to other NASH players such as Allergan (AGN), Intercept Pharmaceuticals (ICPT), and Shire Pharmaceuticals (SHPG).
In Depth Review of Gilead Sciences’ NASH Pipeline Opportunities
Nonalcoholic steatohepatitis (or NASH) doesn’t have any existing approved treatments on the market, but a number of companies are vying for a share of the untapped market.
Allergan Enters the Attractive NASH Market
Although hepatitis C is the most common cause resulting in liver transplants today, NASH (nonalcoholic steatohepatitis) will replace it by 2030.
Understanding Gilead Sciences’ NASH Pipeline
Simtuzumab is Gilead Sciences’ (GILD) most advanced NASH (nonalcoholic steatohepatitis) anti-fibrotic product.
What Explains the Columbia Select Large Cap Growth Fund’s Poor Showing?
The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.
How Are XBI’s Holdings’ Moving Averages Trending?
On June 8, 2016, 77% of XBI’s stocks were trading above their 20-day moving averages, 69% were trading above their 50-day moving averages, and 69% were trading above their 100-day moving averages.
Can XBI Continue the Upward Trend It Achieved in May?
The SPDR S&P Biotech ETF (XBI) reflected the performance of SPY and rose 0.2%, continuing its upward trend. XBI had a good month in May and began June on a positive note.
Ionis’s Metabolic Segment: Phase I and Phase II Studies
Ionis Pharmaceuticals (IONS) is developing drugs for the treatment of various types of metabolic disorders, including diabetes, obesity, and non-alcoholic steatohepatitis.
What’s Ionis Pharmaceuticals Doing with IONIS-TTR?
In March 2010, Ionis entered into a preferred partner alliance with GlaxoSmithKline (GSK) for the development and commercialization of IONIS-TTR.
Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva
Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages
Anacor Pharmaceuticals: $250 Million in Convertible Senior Notes
Anacor Pharmaceuticals rose 7.8% and closed at $61.51 on April 4, 2016. It was trading above its 20-day moving average. Year-to-date, the stock has fallen 45.6%.
Myriad Genetics: Top Performer in the Biotechnology Subgroup
Myriad Genetics (MYGN) rose 9% on November 4, 2015. It reported its fiscal 1Q16 results. Myriad Genetics reported revenue of $183.5 million.
Shire-Dyax Merger Drove Biotech Stocks
Shire (SHPG) announced that it will acquire Dyax (DYAX) for $37.30 per Dyax share in a deal valued at ~$5.9 billion.
ISIS Rose 11.4%, Helped the Biotechnology Subgroup’s Performance
ISIS Pharmaceuticals (ISIS) rose by 11.4% on October 27, 2015. The stock rose due to news of a $5 million milestone payment from GlaxoSmithKline (GSK).
Alnylam Up 2.0% on Phase 1 Initiation of OLE Study with ALT-AT3
Alnylam Pharmaceuticals (ALNY) rose 2.0% on news that it has initiated a Phase I open-label extension (or OLE) study with ALN-AT3 for the treatment of hemophilia and rare bleeding disorders.
Analyzing Juno Therapeutics’ Performance until September 2015
Juno Therapeutics (JUNO) is a mid-cap stock with a market cap of ~$4.75 billion. The stock rose by 8.6%. It outperformed all of the biotech stocks.
ICPT and XON Put Pressure on XBI’s Biotechnology Sector
Intrexon (XON) plummeted by 14.4% after it announced its 2Q15 results. As per the company’s press release, XON’s total revenue was $44.9 million.
